Business Wire

NY-MORGAN-STANLEY

7.2.2024 13:01:35 CET | Business Wire | Press release

Share
Morgan Stanley Inclusive Ventures Lab Hosts Demo Day for Largest, Most Global Cohort of Startups

Morgan Stanley (NYSE: MS) today is hosting its largest global Demo Day, with 23 participating companies from North America and Europe, the Middle East and Africa (EMEA). Cohort companies will pitch over 300 investors, as well as potential business partners and customers.

Over the past five months, the Morgan Stanley Inclusive Ventures Lab has supported its ninth cohort of technology-enabled startups in the seed to Series A funding round stage. The intensive accelerator program provides each company a $250,000 investment (£250,000 in EMEA) from Morgan Stanley, as well as a variety of mentorship opportunities and business-growth resources.

“At a time when startups are facing a challenging funding environment, it is more critical than ever to provide a platform for founders to attract investment and scale their innovative solutions,” said Selma Bueno, Global Head of the Morgan Stanley Inclusive Ventures Group. “Today’s Demo Day showcases the Inclusive Ventures Lab’s largest and most global cohort to date, underscoring our mission to advance a more equitable investment landscape worldwide.”

Companies presenting at Demo Day represent a range of industries including healthcare, customer service, supply chain, recruiting and cybersecurity – with AI and sustainable solutions as cross-cutting themes. Cohort members include: Adauris (Canada), Automated Architecture (UK), Bidrento (Estonia), ByFusion (US), Cult Mia (UK), DotLab (US), eBanqo (Nigeria), Encounter AI (US), FLUIX (US), GigBridge (UK), Health in Her HUE (US), Inicio AI (UK), MEDIjobs (US), Nopalera (US), OKO (Israel), Oppos (Canada), Partsimony (US), Ridelink (Uganda), serviceMob (US), Stak Mobility (US), Tall Poppy (US), Twipes (US) and Unfabled (UK). Learn more about the companies here.

Founded in 2017, the Lab has hosted 92 companies, with a combined valuation of $923MM. Companies have raised $217MM in funding following their participation in the Lab.

Applications for the next Lab cohort will be open from February 7 - March 15, 2024. The tenth cohort will include up to 25 companies, with emphasis on businesses led by overlooked founders providing sustainability-focused products or services. Morgan Stanley will be holding pitch competitions in select cities in North America and EMEA to identify potential Lab participants over the coming months. The next Lab cohort is scheduled to launch in September.

About the Morgan Stanley Inclusive Ventures Lab

The Morgan Stanley Inclusive Ventures Lab (MSIVL) is an intensive five-month in-house accelerator program designed to help further develop and scale startups, culminating in a showcase presentation and Demo Day to the investor community. Morgan Stanley launched MSIVL, formerly called the Multicultural Innovation Lab, in 2017 in order to address inequities in funding of startup founders, which our research shows equals over four trillion dollars in unrealized returns.

About Morgan Stanley

Morgan Stanley is a leading global financial services firm providing a wide range of investment banking, securities, wealth management and investment management services. With offices in 42 countries, the Firm’s employees serve clients worldwide including corporations, governments, institutions and individuals. For further information about Morgan Stanley, please visit www.morganstanley.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240206741043/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Vultr, SUSE & Supermicro Debut Unified Cloud-to-Edge Architecture for Global AI Scaling6.5.2026 14:00:00 CEST | Press release

The strategic partnership bridges the gap between regional cloud and the far edge, combining ruggedized hardware and GitOps-driven Kubernetes to streamline large-scale AI deployments Vultr, the world's largest privately-held cloud infrastructure company, in collaboration with SUSE and Supermicro, today announces a strategic architectural framework designed to solve the complexities of deploying and operating AI workloads across distributed environments. As AI moves closer to the point of data creation - from manufacturing floors to retail storefronts - organizations face significant challenges in latency, cost and operational consistency. This joint initiative provides a seamless, Cloud-to-Edge pipeline that integrates high-performance hardware, localized cloud infrastructure, and unified Kubernetes management. The partnership addresses the reality that sending all data back to a central cloud is no longer viable for real-time AI. The solution breaks down the infrastructure into three

Waiv Enters Collaboration with Daiichi Sankyo to Deliver AI-Derived Biomarkers for ADC Program6.5.2026 14:00:00 CEST | Press release

Waiv, formerly Owkin Dx, to leverage its digital pathology platform encompassing foundation models and AI methodology for ADC biomarker discovery program Waiv, formerly Owkin Dx, a Paris-based company catalyzing AI precision testing, today announced it has entered a collaboration with Daiichi Sankyo (TSE: 4568) to lead digital pathology biomarker discovery for an antibody-drug conjugate (ADC) program. With deep expertise across diverse pathology and multimodal data, and a global data network spanning academic institutions, hospitals, and laboratories, Waiv has a proven track record delivering AI-powered biomarker solutions across the full drug development lifecycle. Under the collaboration, Waiv will apply its end-to-end computational pathology platform to early phase data. This includes tumor microenvironment (TME) analysis across both hematoxylin and eosin (H&E) and immunohistochemistry (IHC) stained samples, as well as biomarker discovery and outcome prediction capabilities aimed at

Elisa Expands PON Deployment with Vecima’s All-PON™ Shelf, Delivering 10G Fiber Services in Estonia6.5.2026 13:30:00 CEST | Press release

Elisa plans to install Vecima’s EXS1610 All-PON shelf across its footprint in Estonia, building on its existing Vecima PON deployment16-port EXS1610 All-PON Shelf supports a variety of PON standards, including GPON, XGS-PON, and 10G-EPON Vecima Networks Inc. (TSX: VCM) announced today that leading telecommunications operator Elisa has deployed Vecima’s Entra EXS1610 All-PON™ Shelf for 10G Fiber-to-the-Home (FTTH) services for its subscribers in Estonia. In Estonia’s competitive broadband market, Elisa brings highly innovative solutions to its subscribers. Vecima’s EXS1610 supports multiple deployment use cases, including greenfield, targeted brownfields, rural edge-outs, hybrid fiber-coax (HFC) overbuilds, footprint extensions, and hub collapses. Its compact shelf footprint can help reduce operating costs and allow operators to deploy anywhere – for maximum flexibility, including data centers, remote cabinets, the headend, and multi-dwelling units. The Entra EXS1610 All-PON Shelf featu

Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia in Germany6.5.2026 13:01:00 CEST | Press release

-The agreement ensures sustainable access to this innovative therapy for eligible patients ages 12 years and older in Germany- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that a reimbursement agreement was signed with the GKV-Spitzenverband for its CRISPR/Cas9 gene-edited therapy, CASGEVY® (exagamglogene autotemcel). This agreement secures sustainable access to this innovative one-time treatment for eligible patients in Germany ages 12 years and older living with severe sickle cell disease or transfusion-dependent beta thalassemia. “For the first time in Germany, a long-term, sustainable access agreement to a gene therapy has been established for people living with sickle cell disease and transfusion-dependent beta thalassemia,” said Ludovic Fenaux, Senior Vice President, Vertex International. “This agreement represents significant progress for people living with these two devastating and life-shortening diseases. We are pleased to collaborate across the health c

Suzano Connects an Area the Size of Over 200,000 Soccer Fields Through Ecological Corridors in Just Four Years6.5.2026 13:00:00 CEST | Press release

Initiative integrates fragments of native forests in the Atlantic Forest, Cerrado and Amazon biomes, stimulating wildlife movement, the expansion of vegetation cover and the restoration of ecosystems Suzano, the world's largest pulp supplier, has connected 214,368 hectares of native forest in the Atlantic Forest, Cerrado, and Amazon biomes in Brazil by establishing ecological corridors, restoring an area larger than 200,000 soccer fields within four years. In 2025 alone, 55,366 hectares of native forest were connected, advancing Suzano’s public goal of connecting 500,000 hectares by 2030, as outlined in the Company’s recently published Sustainability Report. The implementation of ecological corridors is guided by decades of research and monitoring by Suzano and its partners. The aim is to connect larger fragments of land that host greater biodiversity, as well as those already monitored by experts, with sites where wildlife is limited or threatened. These corridors are designed to foll

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye